Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Endometrial Neoplasms

Conditions

Endometrial Neoplasms

Trial Timeline

Apr 11, 2019 → Feb 5, 2025

NCT ID

NCT03884101

About Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin

Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin is a phase 3 stage product being developed by Eisai for Endometrial Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03884101. Target conditions include Endometrial Neoplasms.

What happened to similar drugs?

0 of 20 similar drugs in Endometrial Neoplasms were approved

Approved (0) Terminated (0) Active (20)

🔄Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + DocetaxelDaiichi SankyoPhase 3

🔄Trastuzumab Deruxtecan + ChemotherapyDaiichi SankyoPhase 3

🔄Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3

🔄Pembrolizumab + Lenvatinib + Paclitaxel + DoxorubicinEisaiPhase 3

🔄Puxitatug Samrotecan + Doxorubicin + PaclitaxelAstraZenecaPhase 3

🔄olaparib + durvalumab + durvalumab placebo + olaparib placebo + Carboplatin + PaclitaxelAstraZenecaPhase 3

🔄Olaparib (300 mg BID)AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04865289	Phase 3	Completed	Oct 22, 2019	Jan 14, 2025	Endometrial Neoplasms
NCT03884101	Phase 3	Completed	Apr 11, 2019	Feb 5, 2025	Endometrial Neoplasms

Competing Products

20 competing products in Endometrial Neoplasms

See all competitors

Product	Company	Stage	Hype Score
Atezolizumab - 28 Day Cycle + Bevacizumab + Ipatasertib + Talazoparib + Trastuzumab emtansine + Tiragolumab + Atezolizumab - 21 Day Cycle + Inavolisib + Letrozole + Giredestrant + Abemaciclib	Eli Lilly	Phase 1/2	39
ACR-368 + Gemcitabine	Acrivon Therapeutics	Phase 2	32
Sodium Cridanimod + progestin therapy	Xenetic Biosciences	Phase 2	17
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + Gedatolisib	eFFECTOR Therapeutics	Phase 2	32
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + Docetaxel	Daiichi Sankyo	Phase 3	47
Trastuzumab Deruxtecan + Chemotherapy	Daiichi Sankyo	Phase 3	47
Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + Cisplatin	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
Enfortumab Vedotin	Astellas Pharma	Phase 2	42
Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin	Eisai	Phase 3	40
Lenvatinib	Eisai	Phase 2	35
Pembrolizumab + Lenvatinib + Paclitaxel + Doxorubicin	Eisai	Phase 3	40
E7386 + Lenvatinib + Doxorubicin + Paclitaxel	Eisai	Phase 1/2	36
Abemaciclib + Letrozole	Eli Lilly	Phase 2	39
Abemaciclib + Anastrozole + Letrozole	Eli Lilly	Phase 2	42
LY3023414	Eli Lilly	Phase 2	35
arzoxifene hydrochloride	Eli Lilly	Phase 2	35
Abemaciclib + Letrozole + Pembrolizumab	Eli Lilly	Phase 2	42
Trabectedin + Dexamethasone	Johnson & Johnson	Phase 2	35